Overview

A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-06-30

Target enrollment:

Participant gender:

Summary

The purpose of this Phase II, open-label, multicentre, single-arm study is to assess efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) in participants with locally advanced (Stage III), unresectable non-small cell lung cancer (NSCLC), who have not progressed following platinum-based concurrent or sequential chemoradiotherapy (cCRT or sCRT).

Phase:

PHASE2

Details

Lead Sponsor:

AstraZeneca

Treatments:

durvalumab